Taken together, our results have demonstrated that, first, caspase-11 and caspase-1 partially modulate the expressions of cytokines, chemokines, canonical and noncanonical inflammasome pathway regulators, TI enzymes, and lipid peroxidation enzymes; second, in the context of NASH/NAFLD, caspase-11 has stronger capacities than caspase-1 in modulating inflammatory gene expressions; and third, experimental conditions in caspase-11 deficiency [79] and caspase-1 deficiency [83] were not exactly the same as NASH/NAFLD. The gene discussed is CASP1; the disease is metabolic dysfunction-associated steatotic liver disease.